About 10% of all people are born prematurely, representing a considerable part of the population. These infants are at high risk of life-long brain damage caused by harmful oxygen levels in the brain, which are invisible to the naked eye.
Following a pressing request from the clinical field, OxyPrem develops optical sensors that monitor brain oxygen non-invasively and continuously at next-generation precision. This helps medical teams to react in time and counter inadequate oxygen levels, aiming to prevent irreversible brain damage and life-long disabilities.
In 2020, OxyPrem introduced a first limited series of CE marked devices to the market, which has been used by 38 hospitals across 12 countries until today. OxyPrem NOAH, the second generation of brain oxygen sensors, is expected to be available in early 2025. The company is currently setting up full commercialization of this product, also working with strategic partners and specialized distributors. In parallel, the team is actively engaging in conversations with potential acquisition partners.
To raise funds for CE marking and commercializing the second generation of sensors, OxyPrem is adding a crowdinvesting campaign to its funding mix. The Capital Cell platform approved OxyPrem after completion of a thorough 3-stage due diligence process, consisting of an extensive business case review by 17 members of BioExpert Network, a 92% Intellectual Property score by independent patent attorneys Elion IP, and 80% and 85% scores on market access and regulatory affairs by specialized consultancy Alira Health.
OxyPrem aims to raise a total of EUR 2.3 million including the crowdinvesting campaign. The pre-money valuation is at a good EUR 17 million. The funding round has already got off to a successful start. So far, more than EUR 1.4 million has been invested and a further EUR 100k has been committed. The campaign will run until November.
(SK)